283 related articles for article (PubMed ID: 21381892)
1. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
[TBL] [Abstract][Full Text] [Related]
2. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
Kelaidi C; Beyne-Rauzy O; Braun T; Sapena R; Cougoul P; Adès L; Pillard F; Lamberto C; Charniot JC; Guerci A; Choufi B; Stamatoullas A; Slama B; De Renzis B; Ame S; Damaj G; Boyer F; Chaury MP; Legros L; Cheze S; Testu A; Gyan E; Béné MC; Rose C; Dreyfus F; Fenaux P
Ann Hematol; 2013 May; 92(5):621-31. PubMed ID: 23358617
[TBL] [Abstract][Full Text] [Related]
3. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.
Giraldo P; Nomdedeu B; Loscertales J; Requena C; de Paz R; Tormo M; Navarro P; Benedit P; Gasquet JA;
Cancer; 2006 Dec; 107(12):2807-16. PubMed ID: 17115424
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
Charu V; Belani CP; Gill AN; Bhatt M; Tomita D; Rossi G; Ben-Jacob A
Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
[TBL] [Abstract][Full Text] [Related]
5. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.
Gabrilove J; Paquette R; Lyons RM; Mushtaq C; Sekeres MA; Tomita D; Dreiling L
Br J Haematol; 2008 Jul; 142(3):379-93. PubMed ID: 18540943
[TBL] [Abstract][Full Text] [Related]
6. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
Auerbach M; Silberstein PT; Webb RT; Averyanova S; Ciuleanu TE; Shao J; Bridges K
Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
[TBL] [Abstract][Full Text] [Related]
7. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
9. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
Boccia R; Lillie T; Tomita D; Balducci L
Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
[TBL] [Abstract][Full Text] [Related]
11. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.
Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P;
Br J Haematol; 2006 Jun; 133(5):513-9. PubMed ID: 16681638
[TBL] [Abstract][Full Text] [Related]
12. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
13. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
[TBL] [Abstract][Full Text] [Related]
14. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
15. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes.
Musto P; Lanza F; Balleari E; Grossi A; Falcone A; Sanpaolo G; Bodenizza C; Scalzulli PR; La Sala A; Campioni D; Ghio R; Cascavilla N; Carella AM
Br J Haematol; 2005 Jan; 128(2):204-9. PubMed ID: 15638854
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.
Ichinose Y; Seto T; Nishiwaki Y; Ohe Y; Yamada Y; Takeda K; Saijo N; Hotta T
Jpn J Clin Oncol; 2010 Jun; 40(6):521-9. PubMed ID: 20508073
[TBL] [Abstract][Full Text] [Related]
17. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.
Spiriti MA; Latagliata R; Niscola P; Cortelezzi A; Francesconi M; Ferrari D; Volpe E; Clavio M; Grossi A; Reyes MT; Musto P; Mitra ME; Azzarà A; Pagnini D; D'Arena G; Spadano A; Balleari E; Pecorari P; Capochiani E; De Biasi E; Perego D; Monarca B; Pisani F; Scaramella G; Petti MC
Ann Hematol; 2005 Mar; 84(3):167-76. PubMed ID: 15592833
[TBL] [Abstract][Full Text] [Related]
18. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes.
Stasi R; Abruzzese E; Lanzetta G; Terzoli E; Amadori S
Ann Oncol; 2005 Dec; 16(12):1921-7. PubMed ID: 16166176
[TBL] [Abstract][Full Text] [Related]
19. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.
Nilsson-Ehle H; Birgegård G; Samuelsson J; Antunovic P; Astermark J; Garelius H; Engström LM; Kjeldsen L; Nilsson L; Olsson A; Skov-Holm M; Wallvik J; Gulbrandsen N; Hellström-Lindberg E
Eur J Haematol; 2011 Sep; 87(3):244-52. PubMed ID: 21623919
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
Bustos A; Álvarez R; Aramburo PM; Carabantes F; Díaz N; Florián J; Lázaro M; de Segovia JM; Gasquet JA; Alegre A;
Curr Med Res Opin; 2012 Jan; 28(1):57-67. PubMed ID: 22070513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
